Federico Manuel Daray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federico Manuel Daray has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
Soledad Puppo
Universidad de Buenos Aires, Facultad de Medicina, Instituto de Farmacología, Paraguay 2155, piso 9 (C1121ABG), Ciudad Autónoma de Buenos Aires, Argentina
9 shared publications- Andrea Emilse Errasti
Instituto de Farmacologia, Facultad de Medicina, Universidad de Buenos Aires
8 shared publications Alicia Portela
José Tiburcio Borda Hospital, City of Buenos Aires, Argentina
7 shared publicationsSasha M. Rojas
University of Arkansas, Department of Psychological Science, Fayetteville, United States
7 shared publicationsVera Tifner
Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires. Paraguay 2155 (CP1121), Ciudad Autónoma de Buenos Aires, Argentina
7 shared publicationsAlejandro Olaviaga
Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina; Hospital General de Agudos "Dr. Cosme Argerich", Ciudad de Buenos Aires, Argentina
6 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Brain Behavior and Immunity Integrative
- Vol. 16
Innate Immunity mechanisms in the pathophysiology of bipolar disorder: From evidence to clinical practice
- 23 October 2026
- Published by Elsevier in Brain Behavior and Immunity Integrative
- Vol. 16
Open AccessInnate Immunity mechanisms in the pathophysiology of bipolar disorder: From evidence to clinical practice
- Open Access
- 5 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1004745
Health system use and experience among people with poor mental health: A cross-sectional analysis of the People’s Voice Survey in 18 countries
Background: Across the globe, rates of depression and anxiety have risen substantially since the COVID pandemic. Consequently, poor mental health is now a top health policy priority in many countries and more people than ever are seeking treatment. While the segment of people with poor mental health is large and growing, there is a dearth of data about their demographics and health needs and their use of and experience in the health system. Health systems require this information to effectively organize and provide services. Methods and findings: We investigated population prevalence of fair or poor mental health and compared health system experience and quality of care among adults with poor versus good mental health in 18 high-, middle-, and low-income countries using data from the People’s Voice Survey ( n = 32,419). Data were collected in 2022 and 2023 through a combination of nationally representative telephone, online, and in-person surveys. Prevalence of self-reported poor mental health ranged from 4.7% in Nigeria to 39.6% in China and was unrelated to national income per capita. More women than men reported poor mental health in most countries. Across all countries, people with poor mental health had worse self-rated overall health and more chronic illness. Between 0.9% (Lao PDR) and 52.4% (UK) of those with poor mental health had received mental healthcare in the past year. People with poor mental health reported lower patient activation, worse care quality, and lower confidence in the health system. A study limitation is that results are based on self-reported mental health rather than clinical diagnoses. Conclusions: People with poor mental health have markedly different health profiles and health system experience. These findings should prompt health systems to re-assess their services to better serve this growing patient group. Comparison of user experience and quality over time and across countries with similar health systems may assist in benchmarking performance.
- 5 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1004745
Open AccessHealth system use and experience among people with poor mental health: A cross-sectional analysis of the People’s Voice Survey in 18 countries
Background: Across the globe, rates of depression and anxiety have risen substantially since the COVID pandemic. Consequently, poor mental health is now a top health policy priority in many countries and more people than ever are seeking treatment. While the segment of people with poor mental health is large and growing, there is a dearth of data about their demographics and health needs and their use of and experience in the health system. Health systems require this information to effectively organize and provide services. Methods and findings: We investigated population prevalence of fair or poor mental health and compared health system experience and quality of care among adults with poor versus good mental health in 18 high-, middle-, and low-income countries using data from the People’s Voice Survey ( n = 32,419). Data were collected in 2022 and 2023 through a combination of nationally representative telephone, online, and in-person surveys. Prevalence of self-reported poor mental health ranged from 4.7% in Nigeria to 39.6% in China and was unrelated to national income per capita. More women than men reported poor mental health in most countries. Across all countries, people with poor mental health had worse self-rated overall health and more chronic illness. Between 0.9% (Lao PDR) and 52.4% (UK) of those with poor mental health had received mental healthcare in the past year. People with poor mental health reported lower patient activation, worse care quality, and lower confidence in the health system. A study limitation is that results are based on self-reported mental health rather than clinical diagnoses. Conclusions: People with poor mental health have markedly different health profiles and health system experience. These findings should prompt health systems to re-assess their services to better serve this growing patient group. Comparison of user experience and quality over time and across countries with similar health systems may assist in benchmarking performance.
- 18 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (4) , 1970-1982
Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice
Ketamine has emerged as a rapid and sustained treatment for Major Depressive Disorder (MDD) and an alternative for patients who have not responded to traditional therapies. Its effects have been partly attributed to the noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) in the central nervous system, which enhances neuroplasticity. However, the etiopathology of MDD is complex, and substantial evidence suggests that inflammation may significantly contribute to the initiation and maintenance of MDD. Furthermore, the rapid and sustained antidepressant effect of ketamine may be attributed to its anti-inflammatory and immunomodulatory actions. To investigate the antidepressant and anti-inflammatory effect of ketamine, we used a lipopolysaccharide (LPS)-induced depressive-like murine model. The Tail Suspension Test (TST) and Sucrose Preference Test (SPT) were conducted to assess depressive-like behaviors. Additionally, cellular immunophenotyping of blood, spleen, and brain was performed by flow cytometry. Ketamine administration (10–20 mg/kg) alleviated despair and anhedonia in LPS-depressive-like mice, as evidenced by the TST and SPT tests. Behavioral changes were accompanied by the reduction of Ly6G+ neutrophils and an increment of anti-inflammatory Ly6Clow/neg monocytes in the blood. Ketamine treatment also reduced CD45highLy6GnegLy6Chigh monocyte infiltration into the brain and dampened microglial activation (CD45lowCD11bhigh). In the spleen, ketamine decreased the expansion of acute T lymphocyte response (CD3+CD4negCD8neg) induced by LPS, while increasing the percentage of CD4+CD69+TIM-3+ lymphocytes, known for their regulatory function. Splenic macrophages were also polarized towards an anti-inflammatory CD206+M2-phenotype with ketamine. Finally, we showed that the anti-inflammatory and antidepressant effects are linked, perhaps as convergent outcomes, by using another NMDA receptor antagonist, MK-801, and the mTOR signaling inhibitor, rapamycin. These findings highlight ketamine’s multifaceted mechanisms of action, underscoring its potential as a treatment for MDD, particularly in patients with significant inflammation.
- 18 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (4) , 1970-1982
Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice
Ketamine has emerged as a rapid and sustained treatment for Major Depressive Disorder (MDD) and an alternative for patients who have not responded to traditional therapies. Its effects have been partly attributed to the noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) in the central nervous system, which enhances neuroplasticity. However, the etiopathology of MDD is complex, and substantial evidence suggests that inflammation may significantly contribute to the initiation and maintenance of MDD. Furthermore, the rapid and sustained antidepressant effect of ketamine may be attributed to its anti-inflammatory and immunomodulatory actions. To investigate the antidepressant and anti-inflammatory effect of ketamine, we used a lipopolysaccharide (LPS)-induced depressive-like murine model. The Tail Suspension Test (TST) and Sucrose Preference Test (SPT) were conducted to assess depressive-like behaviors. Additionally, cellular immunophenotyping of blood, spleen, and brain was performed by flow cytometry. Ketamine administration (10–20 mg/kg) alleviated despair and anhedonia in LPS-depressive-like mice, as evidenced by the TST and SPT tests. Behavioral changes were accompanied by the reduction of Ly6G+ neutrophils and an increment of anti-inflammatory Ly6Clow/neg monocytes in the blood. Ketamine treatment also reduced CD45highLy6GnegLy6Chigh monocyte infiltration into the brain and dampened microglial activation (CD45lowCD11bhigh). In the spleen, ketamine decreased the expansion of acute T lymphocyte response (CD3+CD4negCD8neg) induced by LPS, while increasing the percentage of CD4+CD69+TIM-3+ lymphocytes, known for their regulatory function. Splenic macrophages were also polarized towards an anti-inflammatory CD206+M2-phenotype with ketamine. Finally, we showed that the anti-inflammatory and antidepressant effects are linked, perhaps as convergent outcomes, by using another NMDA receptor antagonist, MK-801, and the mTOR signaling inhibitor, rapamycin. These findings highlight ketamine’s multifaceted mechanisms of action, underscoring its potential as a treatment for MDD, particularly in patients with significant inflammation.
- Open Access
- 12 September 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (2) , 1-14
Prediction of fatal and non-fatal suicide attempts by the Columbia Suicide Severity Rating Scale (C-SSRS): systematic review and meta-analysis
Background: The Columbia Suicide Severity Rating Scale (C-SSRS) is a predominant tool for screening and scoring suicidal ideation and behaviour to identify individuals at risk. No meta-analysis has examined its predictive significance. Aims: To evaluate the C-SSRS assessment of suicidal ideation and suicidal behaviour as predictors of future fatal and non-fatal suicide attempts. Method: A systematic search of Medline, PsycInfo, Embase, and Health and Psychosocial Instruments databases was conducted from January 2008 to February 2024. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and the study was registered in PROSPERO (CRD42022361944). Two independent reviewers screened and extracted data, and assessed the risk of bias. Pooled odds ratios were calculated using random-effects models, and heterogeneity was assessed with the I2 statistic. Publication bias was evaluated with Egger’s test and funnel plots. Results: The search identified 1071 unique records, of which 28 studies met inclusion criteria. The meta-analysis included 27 studies with independent samples. Suicidal behaviour (pooled odds ratio 3.14, 95% CI 1.86–5.31) and suicide attempts (pooled odds ratio 2.78, 95% CI 1.82–4.24) were predictors of future non-fatal suicide attempts. Suicidal ideation severity (odds ratio 1.46/point, 95% CI 1.28–1.77) was a stronger predictor of future non-fatal suicide attempts than suicideal ideation intensity (odds ratio 1.11/point, 95% CI 1.04–1.18). Two studies linked higher suicidal ideation severity and a history of suicidal behaviour with an increased risk of fatal suicide attempts, though meta-analysis was not feasible for only two studies. Conclusions: Suicidal behaviour, suicide attempts and to a lesser extent suicidal ideation, identified using the C-SSRS, predicted future non-fatal suicide attempts. These findings support the use of the C-SSRS to detect individuals at higher-risk requiring enhanced preventive interventions.
- 12 September 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (2) , 1-14
Open AccessPrediction of fatal and non-fatal suicide attempts by the Columbia Suicide Severity Rating Scale (C-SSRS): systematic review and meta-analysis
Background: The Columbia Suicide Severity Rating Scale (C-SSRS) is a predominant tool for screening and scoring suicidal ideation and behaviour to identify individuals at risk. No meta-analysis has examined its predictive significance. Aims: To evaluate the C-SSRS assessment of suicidal ideation and suicidal behaviour as predictors of future fatal and non-fatal suicide attempts. Method: A systematic search of Medline, PsycInfo, Embase, and Health and Psychosocial Instruments databases was conducted from January 2008 to February 2024. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and the study was registered in PROSPERO (CRD42022361944). Two independent reviewers screened and extracted data, and assessed the risk of bias. Pooled odds ratios were calculated using random-effects models, and heterogeneity was assessed with the I2 statistic. Publication bias was evaluated with Egger’s test and funnel plots. Results: The search identified 1071 unique records, of which 28 studies met inclusion criteria. The meta-analysis included 27 studies with independent samples. Suicidal behaviour (pooled odds ratio 3.14, 95% CI 1.86–5.31) and suicide attempts (pooled odds ratio 2.78, 95% CI 1.82–4.24) were predictors of future non-fatal suicide attempts. Suicidal ideation severity (odds ratio 1.46/point, 95% CI 1.28–1.77) was a stronger predictor of future non-fatal suicide attempts than suicideal ideation intensity (odds ratio 1.11/point, 95% CI 1.04–1.18). Two studies linked higher suicidal ideation severity and a history of suicidal behaviour with an increased risk of fatal suicide attempts, though meta-analysis was not feasible for only two studies. Conclusions: Suicidal behaviour, suicide attempts and to a lesser extent suicidal ideation, identified using the C-SSRS, predicted future non-fatal suicide attempts. These findings support the use of the C-SSRS to detect individuals at higher-risk requiring enhanced preventive interventions.
- 9 August 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 407, 578719
sTREM2 as a mediator in the association between life-threatening events and depression
- 9 August 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 407, 578719
sTREM2 as a mediator in the association between life-threatening events and depression
- 22 March 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (5) , 103563
Unbalanced CD4+IL-10+ and more activated and exhausted CD8+ lymphocytes characterized patients with a major depressive episode
- 22 March 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (5) , 103563
Unbalanced CD4+IL-10+ and more activated and exhausted CD8+ lymphocytes characterized patients with a major depressive episode
- 6 March 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 184, 272-278
Monocyte profiles and their association with depression severity and functional disability
- 6 March 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 184, 272-278
Monocyte profiles and their association with depression severity and functional disability
- 2 December 2024
- Published by Elsevier in Psychiatry Research
- Vol. 343, 116310
Incidence rate of suicidal behavior stratified by diagnosis among high-risk patients
- 2 December 2024
- Published by Elsevier in Psychiatry Research
- Vol. 343, 116310
Incidence rate of suicidal behavior stratified by diagnosis among high-risk patients
- 17 August 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 18-24
Comparing suicide risk screening strategies in Spanish-speaking pediatric patients
- 17 August 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 18-24
Comparing suicide risk screening strategies in Spanish-speaking pediatric patients